Closing of the first stage of the binding agreement of investment in and acquisition in stages of IOPtima

Tel Aviv (March 29, 2018) – Further to BioLight’s announcement dated November 21, 2017, regarding signing a binding agreement for the investment in and the acquisition in stages of its subsidiary IOPtima Ltd. (the “Agreement”) by the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co. (the “Acquirer”), the first stage …

Continue reading

Update regarding Closing of the first stage of the Binding agreement of investment in and acquisition of IOPtima

Tel Aviv (February 11, 2018) – Further to BioLight’s announcement dated November 31, 2017 regarding signing a binding agreement for the investment in and the acquisition in stages of its subsidiary IOPtima (the “Agreement”) by the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co. (“the Acquirer”), and in accordance with …

Continue reading

DiagnosTear Ltd. – Recruitment of the first participant for clinical trial using the TeaRx ™ technology

The Company hereby announces that on August 31, 2017, DiagnosTear Ltd. (“DiagnosTear”) announced the recruitment of a first participant for an additional clinical trial to examine a product based on the TeaRx ™ technology, which is used to diagnose, personalize treatment and monitoring Dry eye syndrome by examining the composition …

Continue reading